Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (\~30%) will undergo imaging with standardized intervals.
Checked against the public recordLast updated Jul 16, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- N-Power Medicine
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
INCLUSION CRITERIA * Be ≥18 years of age at the time of informed consent * Evidence of a confirmed diagnosis of EGFR mutant (EGFR exon 19del or EGFR exon 21 L858R) locally advanced or metastatic NSCLC diagnosed on Jan 1st 2024 or later. EXCLUSION CRITERIA * ECOG≥2 at diagnosis of advanced or metastatic NSCLC * Evidence of prior treatment with osimertinib, amivantamab or lazertinib. For the planned selection and analysis of external controls, further eligibility criteria will be applied according to the COPERNICUS SAP.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Pacific Cancer CareMonterey, California
- Torrance Memorial Physician Network-Cancer CareTorrance, California
- John Muir HealthWalnut Creek, California
- Bayhealth Cancer Center- KentDover, Delaware
- Bayhealth Cancer Center- SussexMilford, Delaware
- Kootenai Clinic Cancer Services Coeur d'AleneCoeur d'Alene, Idaho
- Northwest Oncology & HematologyElk Grove Village, Illinois
- Lankenau Medical CenterPaoli, Pennsylvania
- Oncology Consultants, P.A.Houston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 16, 2026. Always confirm current availability with the study team.